If you have Type 2 diabetes or qualifying cardiovascular disease, your chances of Part D coverage are meaningfully better than if your prescription is based on weight loss alone
Some studies indicate GLP-1s may reduce the risk of substance use disorders (Nature Medicine), neurocognitive disorders (including Alzheimers disease), infectious diseases, some respiratory conditions and certain cancers (JAMA Oncology)
Phase II study to evaluate the efficacy and safety of rilotumumab and bevacizumab in subjects with recurrent malignant glioma
A pivotal study (Yano et al., Cell, 2015) showed that the microbiota influence the serotonergic system through an entire constellation of metabolites many produced by spore-forming Clostridia, the same group known for butyrate and broad gut-supportive functions
Life Extension - Why We Do It
Senescent cells can play a role in cancer prevention